NCT00416351View on ClinicalTrials.gov

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 27, 2006

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
LeukemiaLymphomaSmall Intestine Cancer
Interventions
DRUG

clofarabine

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Rochester

OTHER

collaborator

The Cleveland Clinic

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00416351 - Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | Biotech Hunter | Biotech Hunter